KR101519675B1 - 균막 형성을 처리하기 위한 트리아졸 화합물 - Google Patents

균막 형성을 처리하기 위한 트리아졸 화합물 Download PDF

Info

Publication number
KR101519675B1
KR101519675B1 KR1020097024151A KR20097024151A KR101519675B1 KR 101519675 B1 KR101519675 B1 KR 101519675B1 KR 1020097024151 A KR1020097024151 A KR 1020097024151A KR 20097024151 A KR20097024151 A KR 20097024151A KR 101519675 B1 KR101519675 B1 KR 101519675B1
Authority
KR
South Korea
Prior art keywords
compound
lower alkyl
iron
cystic fibrosis
aeruginosa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097024151A
Other languages
English (en)
Korean (ko)
Other versions
KR20100017153A (ko
Inventor
데이비드 레이드
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38534753&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101519675(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20100017153A publication Critical patent/KR20100017153A/ko
Application granted granted Critical
Publication of KR101519675B1 publication Critical patent/KR101519675B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020097024151A 2007-05-22 2008-05-21 균막 형성을 처리하기 위한 트리아졸 화합물 Expired - Fee Related KR101519675B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07108650.8 2007-05-22
EP07108650A EP1994930A1 (en) 2007-05-22 2007-05-22 Triazol compounds for treating biofilm formation
PCT/EP2008/056231 WO2008142094A1 (en) 2007-05-22 2008-05-21 Triazol compounds for treating biofilm formation

Publications (2)

Publication Number Publication Date
KR20100017153A KR20100017153A (ko) 2010-02-16
KR101519675B1 true KR101519675B1 (ko) 2015-05-12

Family

ID=38534753

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097024151A Expired - Fee Related KR101519675B1 (ko) 2007-05-22 2008-05-21 균막 형성을 처리하기 위한 트리아졸 화합물

Country Status (18)

Country Link
US (2) US8309590B2 (enExample)
EP (3) EP1994930A1 (enExample)
JP (1) JP5470245B2 (enExample)
KR (1) KR101519675B1 (enExample)
CN (2) CN103381271A (enExample)
AU (1) AU2008252964B2 (enExample)
BR (1) BRPI0811103A2 (enExample)
CA (1) CA2685112A1 (enExample)
CL (1) CL2008001469A1 (enExample)
IL (1) IL201832A (enExample)
MA (1) MA31388B1 (enExample)
MX (1) MX2009012628A (enExample)
NZ (1) NZ580735A (enExample)
RU (1) RU2478385C2 (enExample)
TN (1) TN2009000487A1 (enExample)
TW (1) TWI419690B (enExample)
WO (1) WO2008142094A1 (enExample)
ZA (1) ZA200907415B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB2463181B (en) 2007-05-14 2013-03-27 Univ New York State Res Found Induction of a physiological dispersion response in bacterial cells in a biofilm
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
TWI415572B (zh) 2011-06-17 2013-11-21 Univ Chang Gung 利用１，２，３，４，６－五－ｏ－沒食子醯基－ｄ－葡哌喃糖來抑制生物膜形成
US10028933B2 (en) * 2015-07-22 2018-07-24 Ohio State Innovation Foundation Compositions and methods for inhibiting the growth of multi-drug resistant microbes
RU2646488C2 (ru) * 2016-04-25 2018-03-05 Государственное бюджетное образовательное учреждение высшего профессионального образования "Оренбургский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО ОрГМУ Минздрава России) Средство для селективного влияния на биопленкообразование микроорганизмами
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
CN110448693A (zh) * 2019-07-30 2019-11-15 华东理工大学 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507601A (ja) * 1996-06-25 2000-06-20 ノバルティス アクチエンゲゼルシャフト 置換３，５―ジフェニル―１，２，４―トリアゾールおよび製薬的金属キレート化剤としてのその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004438A (en) * 1991-12-31 1999-12-21 3M Innovative Properties Company Biofilm reduction sterilizer
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
WO1997049397A1 (en) * 1996-06-26 1997-12-31 Sankyo Company, Limited Novel medicinal compositions of hydropyridines
US6759040B1 (en) * 1997-09-12 2004-07-06 University Of Maryland, College Park Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures
WO2001070213A2 (en) 2000-03-23 2001-09-27 Influx, Inc. Bactericidal antimicrobial methods and compositions for use in treating gram positive infections comprising an antibiotic potentiator having acyl hydrazide oxy amide or 8-hydroxy quinoline structure
WO2002076439A2 (en) * 2001-03-23 2002-10-03 The Board Of Trustees Of The University Of Illinois Compounds capable of modulating the activity of multidrug transporters and therapeutic use of the same
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
GB0205593D0 (en) * 2002-03-09 2002-04-24 Univ Nottingham Treatment of surfaces populated by bacteria
US20040043052A1 (en) * 2002-05-24 2004-03-04 Angiotech Pharmaceuticals, Inc. Compositions and methods for coating medical implants
US7498292B2 (en) 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507601A (ja) * 1996-06-25 2000-06-20 ノバルティス アクチエンゲゼルシャフト 置換３，５―ジフェニル―１，２，４―トリアゾールおよび製薬的金属キレート化剤としてのその使用

Also Published As

Publication number Publication date
TN2009000487A1 (en) 2011-03-31
RU2009147297A (ru) 2011-06-27
MX2009012628A (es) 2009-12-07
JP5470245B2 (ja) 2014-04-16
US20100152101A1 (en) 2010-06-17
EP2253317A2 (en) 2010-11-24
AU2008252964A1 (en) 2008-11-27
BRPI0811103A2 (pt) 2014-12-09
NZ580735A (en) 2012-02-24
US8309590B2 (en) 2012-11-13
KR20100017153A (ko) 2010-02-16
JP2010527960A (ja) 2010-08-19
CN101678004A (zh) 2010-03-24
ZA200907415B (en) 2010-07-28
US8592473B2 (en) 2013-11-26
MA31388B1 (fr) 2010-05-03
EP1994930A1 (en) 2008-11-26
IL201832A0 (en) 2010-06-16
RU2478385C2 (ru) 2013-04-10
AU2008252964B2 (en) 2011-12-01
CL2008001469A1 (es) 2010-10-29
IL201832A (en) 2015-11-30
WO2008142094A1 (en) 2008-11-27
TWI419690B (zh) 2013-12-21
TW200913996A (en) 2009-04-01
EP2162130A1 (en) 2010-03-17
EP2253317A3 (en) 2011-03-16
CN103381271A (zh) 2013-11-06
WO2008142094A4 (en) 2009-01-29
CA2685112A1 (en) 2008-11-27
US20120329746A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
KR101519675B1 (ko) 균막 형성을 처리하기 위한 트리아졸 화합물
AU2017201670B2 (en) A composition comprising an antibiotic and a dispersant or an anti-adhesive agent
CN101951868A (zh) 用于治疗阴道感染和致病性阴道生物被膜的组合物和方法
JP2010527960A5 (enExample)
US20060073156A1 (en) Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract
AU2012201134B2 (en) Triazol compounds for treating biofilm formation
HK1146223A (en) Triazol compounds for treating biofilm formation
GB2554742A (en) Treatment
HK1220911B (en) A composition comprising a non-peptide antibiotic and cysteamine
HK1185015B (en) A composition comprising an antibiotic and a dispersant

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20180507

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20180507

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000